adverse effect
Conditions
Interventions
None listed
Sponsors
Tergooiziekenhuizen Hilversum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age 70 years or older. Admitted for a hip fracture or other fall- related fracture on the department of Surgery or Orthopaedics. Inclusion within 24 hours after admission on the department. The patient or representative speaks either Dutch or English. Patient or representative must be able to give informed consent
Exclusion criteria
Exclusion criteria: Use of an antipsychotic agent within 90 days before hospital admission. Patient is not undergoing surgery for the hip fracture or other fall- related fracture. Start or dose changes in the following medication in the 14 days before admission: Thrombocyte aggregation inhibitors QT- prolongating drugs Antidiabetic drugs Antihypertensive drugs Cholesterol- lowering drugs Additional for recording a holter electrocardiogram (ECG) for patients in subgroup 1: History of pacemaker implantation, atrial fibrillation, bundle branch block, congenital QT- syndrome. Use of QT prolongating drugs (CERT list 1 www.azcert.org) in the 14 days before admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. Serum level of fastening glucose (mmol/l). b. QT interval measured by (holter) ECG using Fridericia*s formula . | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum level of triglycerides (mmol/l). 2. Closure time (sec), measured by Platelet Functional Analyser (PFA-100). 3. Serum concentration haloperidol (µg/ L). 4. Daily defined dose, total antipsychotic exposure in haloperidol users. 5. Genetic polymorphisms at D2 receptor, serotonin 2c receptor, methylenetetrahydrofolate reductase (MTHFR), NUBPL and NOS1AP genes. | — |
Countries
Netherlands
Outcome results
None listed